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Interstitial lung disease (ILD) is a commonly encountered complication of systemic sclerosis (SSc) and accounts for a signiﬁcant
proportion of SSc-associated morbidity and mortality. Its pathogenesis remains poorly understood, and therapies that treat SSc
ILD are suboptimal, at best. SSc ILD pathogenesis may share some common mechanisms with other ﬁbrotic lung diseases, in
which dysregulation of lung epithelium can contribute to pathologic ﬁbrosis via recruitment or in situ generation and activation
of ﬁbroblasts. TGFβ, a master regulator of ﬁbrosis, is tightly regulated in the lung by the integrin αvβ6 ,w h i c hi se x p r e s s e da tl o w
levels on healthy alveolar epithelial cells but is highly induced in the setting of lung injury or ﬁbrosis. Here we discuss the biology
of αvβ6 and present this integrin as a potentially attractive target for inhibition in the setting of SSc ILD.
1.Introduction
Systemic sclerosis (SSc), also known as scleroderma, is
a connective tissue disease of unknown etiology that is char-
acterized by ﬁbroproliferative changes in multiple organs,
as well as microvascular and immunologic dysregulation.
One of the most morbid conditions associated with SSc is
interstitial lung disease (ILD), which occurs in 25–90% of
SSc patients, depending on the detection methods used and
the demographics of the population being studied [1, 2].
The pathologic mechanisms responsible for the initiation
and maintenance of SSc ILD remain poorly characterized.
Approximately 42% of patients with SSc ILD will die of
disease progression within 10 years of diagnosis [3], and
currently no curative therapies exist to combat this morbid
complication.
2. Mechanisms of Fibrosisin SSc:
A Role for EpithelialCells?
Much of the research literature on SSc-associated ﬁbrosis has
focused on the roles of ﬁbroblasts and myoﬁbroblasts, the
eﬀector cells that are ultimately involved in the production
of collagen and other extracellular matrix (ECM) proteins.
However, the development of ﬁbrosis in SSc is indeed a
complex process involving crosstalk amongst multiple cell
types, including epithelial, endothelial, immune, and mes-
enchymalcelltypes.Inidiopathicpulmonaryﬁbrosis(IPF),a
progressive ﬁbrosing lung disease that has a median survival
of between two and three years [4], the principle defect
is thought to be recurrent epithelial injury with resultant
epithelial cell senescence and/or apoptosis. Epithelial injury
can lead to the recruitment and activation of ﬁbroblasts,
which can be derived from resident ﬁbroblasts, circulating
ﬁbrocytes, or the diﬀerentiation of epithelial cells, endothe-
lial cells, or pericytes into ﬁbroblasts. The best characterized
of these changes in cell diﬀerentiation involves epithelial cells
and has been termed epithelial-to-mesenchymal transition
(EMT). Alveolar type II epithelial cell (AT2) injury has long
been observed in lung biopsies from patients with ILD, and
recent animal data suggests a causal relationship between
AT2 injury and ﬁbrosis. Sisson et al. recently demonstrated
that targeted deletion of AT2 cells, using diphtheria toxin
drivenbyaspeciﬁclungepithelialcellpromoterleadsdirectly2 International Journal of Rheumatology
to lung ﬁbrosis [5]. The most convincing evidence for the
contribution of EMT to lung ﬁbrosis came from studies
by Kim et al., who used genetic fate-mapping methods
to demonstrate the capacity of alveolar epithelial cells to
undergo EMT in an established mouse model of lung
ﬁbrosis [6]. Based on these data and others, injured alveolar
epithelial cells are viewed as potential drivers of pathologic
pulmonary ﬁbrosis.
Prior studies have provided evidence for increased
epithelial cell damage in SSc ILD. Wells et al. measured
the speed of clearance of technetium-labeled diethylene-
triamine-pentaacetate (99mTc-DTPA) from the lungs in 53
patients with SSc ILD and found that rapid clearance,
which suggested breach of epithelial barrier function, was
associated with more dramatic clinical deterioration whereas
normal clearance predicted stable disease [7]. Serum levels
of the mucin-like glycoprotein KL-6, which is produced
exclusively by lung epithelial cells and is associated with lung
epithelial cell damage, are increased in ILD associated with
connective tissue diseases [8].
Recurrent lung epithelial injury via chronic microaspi-
ration has been proposed as a mechanism contributing to
lung ﬁbrosis. After the skin, the most commonly aﬀected
organ system in SSc is the gastrointestinal tract, aﬀecting
approximately 50–90% of all patients [9–11]. The esophagus
is the most frequently involved site of the GI tract, leading
to gastroesophageal reﬂux (GER). In a rodent model,
chronic gastric ﬂuid aspiration leads to a lymphocytic and
obliterative bronchiolitis as well as parenchymal ﬁbrosis,
with increased TGFβ levels in bronchoalveolar lavage ﬂuid
[12]. Intriguingly, these histologic changes are independent
of gastric ﬂuid pH. The bile acid chenodeoxycholic acid
stimulates TGFβ production in human airway epithelial
cells and induces ﬁbroblast proliferation in vitro in a
TGFβ-dependent manner [13]. Correlative data support a
relationship between chronic microaspiration and SSc ILD
as well as other ﬁbrotic lung diseases such as IPF [14, 15]. A
strong association between GER and IPF has been recently
reported in several studies, with an estimated prevalence
of 67–88% for distal esophageal reﬂux and 30–71% for
proximal esophageal reﬂux based on 24-hour esophageal
pH monitoring. Interestingly, symptoms of reﬂux were poor
predictors for the diagnosis of GER, implying a signiﬁ-
cant component of silent microaspiration [16–18]. Besides
microaspiration, other mechanisms leading to lung ﬁbrosis
could also be at play in SSc ILD, involving not only epithelial
cells but also endothelial, mesenchymal, and immune cell
types. However, the hypothesis that microaspiration leads
to SSc pulmonary ﬁbrosis via recurrent epithelial injury
is certainly an important one that needs to be strongly
considered, especially given the prevalence of GER in SSc.
3. TGFβ: A Critical Mediator of Fibrosis
TGFβ is a pleiotropic cytokine that aﬀects cell prolifer-
ation, diﬀerentiation, and apoptosis and is involved in
a multitude of homeostatic functions. Importantly, TGFβ
is regarded as the “master switch” of ﬁbrosis in many
tissues, including the lung [19]. The major eﬀects of TGFβ
includeinhibitionofepithelialcellproliferation,inductionof
ﬁbroblast proliferation and the expression of genes encoding
components of the ECM, and inhibition of the expression
of metalloproteinase genes. TGFβ can stimulate ﬁbroblast
conversion into contractile myoﬁbroblasts, which actively
produce collagen and other ECM proteins, and may serve
as an inducer of EMT, leading to ﬁbrosis [20]. Mice that
possess a gain of function mutation in the TGFβ pathway
develop progressive ﬁbrosis in multiple organs resembling
SSc [21]. Global deletion of Smad3, a critical mediator of
TGFβ signaling, or speciﬁc deletion of the TGFβ receptor
II from lung epithelial cells aﬀords resistance to bleomycin-
induced lung ﬁbrosis [22, 23].
Much data underscores the importance of TGFβ in SSc-
associated ﬁbrosis [24]. Increased expression of TGFβ1o r
TGFβ2 is seen in early skin lesions and in lung tissue from
patients with SSc ILD [25, 26], and TGFβ1 was signiﬁcantly
elevated in bronchoalveolar lavage ﬂuid from SSc patients
with pulmonary ﬁbrosis [27] .Ac r i t i c a lr o l ef o rT G F β in
SSc has been highlighted by DNA microarray studies of
SSc skin and ﬁbroblasts. Recently, Sargent et al. generated a
TGFβ-responsive signature in dermal ﬁbroblasts comprised
of 894 responsive genes [28]. Analysis of these genes in SSc
skin biopsies revealed that this TGFβ-responsive signature
occurredexclusivelyinasubsetofskinbiopsiesfrompatients
with diﬀuse SSc, and in particular, those who had a higher
incidence of lung ﬁbrosis. Importantly, these data suggest
thatasubsetofSScpatientshasdiseasethatispredominantly
driven by TGFβ.
4. Regulation of TGFβ by αvβ6
There are three isoforms of TGFβ in mammals which are all
bind to the same heteromeric receptor, leading to activation
of the canonical pathway via phosphorylation of Smad
proteins. In addition, noncanonical pathways are activated
by TGFβ receptors, including several protein kinases (p38,
JNK,Erk,c-Abl,TGF-β-activatedkinase)andthelipidkinase
PI3 kinase and its downstream target Akt. However, the
phenotypes of mice lacking the diﬀerent TGFβ isoforms
are disparate, which could be explained by diﬀerences in
isoformexpressionpatternsordiﬀerentialregulationofnon-
canonical signaling pathways.
Mice deﬁcient in TGFβ1 exhibit uncontrolled tissue
inﬂammation, autoimmunity, and premature death, demon-
stratingacriticalroleforTGFβ1inimmunehomeostasis[29,
30].ThesedatasuggestthatgeneralblockadeofTGFβ should
be approached with caution. A clinical trial of SSc patients
utilizing an antibody directed against TGFβ1 showed no
appreciable therapeutic eﬀect [31], although the potency
of this antibody has been questioned. Given its pleiotropic
eﬀects, TGFβ inhibition using strategies targeted to speciﬁc
regions involved in ﬁbrosis might be a better alternative.
Most other approaches currently under consideration for
targeting TGFβ block either TGFβ receptors or TGFβ itself.
These approaches might lead to unwanted side eﬀects by
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sites outside the organs aﬀected by tissue ﬁbrosis. Although
mice lacking αvβ6 do have mild inﬂammation in the lungs
and skin, these eﬀects are much less severe than those seen
in mice lacking even a single TGFβ isoform. Additionally,
the αvβ6 integrin is highly upregulated in diseased tissue
providing a mechanism for injury-induced TGFβ activation
as compared to homeostatic control of TGFβ activity. By
inhibiting only a subset of TGFβ activation, particularly
in injured epithelial organs, targeting αvβ6 could allow
treatment of tissue ﬁbrosis with substantially reduced risk
ofdisruptingbeneﬁcialhomeostaticcontrolofinﬂammation
and immunity.
The regulation of TGFβ activity involves multiple inter-
actions of various proteins with the TGFβ cytokine. TGFβ is
normally secreted as a complex which includes the bioactive
peptide of TGFβ1, an amino terminal fragment of the
TGFβ1 gene product called the latency-associated peptide
(LAP), and the latent TGFβ-binding protein (LTBP) [32].
The TGFβ gene product is cleaved within the endoplasmic
reticulum by the endopeptidase, furin, and it is assembled as
a complex of two disulﬁde-linked homodimers formed from
the shorter carboxy-terminal fragment (the active cytokine)
and the longer amino-terminal fragment, LAP. These two
homodimersassociatenoncovalentlytoformthesmalllatent
complex, which is unable to activate the TGFβ receptor
because LAP shields the mature TGFβ homodimer from
interaction with its receptor. In most cells, this small latent
complex becomes disulﬁde linked to one of the latent TGFβ-
binding proteins (LTBP). This large complex is secreted and
attaches to components of the extracellular matrix and is
covalently cross-linked to ECM proteins via the action of
extracellular tissue transglutaminase. This preformed latent
TGFβ complex exists at a high concentration in the ECM
of most organs with little evidence of TGFβ activation [33].
GiventhediverseandpotenteﬀectsofTGFβ,itsactivitymust
be tightly regulated in a spatially speciﬁc manner.
Integrins are cell surface molecules comprised of alpha
and beta chain heterodimers that regulate cell adhesion, sur-
vival,proliferation,andmigration[34].Pulmonaryepithelial
cells express at least 8 distinct integrin heterodimers. The
α3β1a n dα6β4 integrins recognize the epithelial basement
protein, laminin 5 and play an important role in main-
tenance of epithelial integrity [35–38]. The other 6-lung
epithelial integrins recognize ligands that are not present
at baseline but are components of the provisional matrix
that are upregulated in response to injury or inﬂammatory
stimuli. The αvβ6 integrin is the only integrin that is
restricted in its expression to epithelial cells. This integrin,
minimally expressed in healthy airway and alveolar epithelial
cellsatbaseline,getsrapidlyinducedatthesesitesinresponse
to a variety of insults, including lung injury [39]. Notably,
and of possible relevance to the skin ﬁbrosis of SSc, αvβ6i s
also upregulated on keratinocytes in the setting of wound
healing but is minimally expressed at baseline [40]. In
vitro, the αvβ6 integrin binds to a number of ligands,
including ﬁbronectin, tenascin-C, and osteopontin [41]v i a
interactions with an arginine-glycine-aspartic acid (RGD)
tripeptide sequence, a sequence also recognized by several
other integrins including those that share the αv subunit
[42].However,theinvivorelevanceofαvβ6interactionswith
these ligands remains uncertain.
Mice completely lacking the β6 integrin subunit,
which pairs exclusively with the αv subunit, were viable
with a near-normal life expectancy, but developed low-grade
inﬂammation of the skin and lungs and late-onset emphy-
sema [43, 44]. Following intratracheal delivery of bleomycin,
a drug used to induce pulmonary ﬁbrosis, β6 deﬁcient mice
developed exaggerated inﬂammation in the lung but were
remarkably protected from the subsequent development of
pulmonary ﬁbrosis [45] .T h e s em i c ew e r ea l s od r a m a t i c a l l y
protected from radiation-induced pulmonary ﬁbrosis [46].
These phenotypic ﬁndings suggested a role for the αvβ6
integrin in regulating TGFβ, a key negative regulator of
inﬂammation but a positive regulator of ﬁbrosis. Amino acid
sequence analysis revealed the presence of an RGD-binding
sequence in the latency-associated peptide (LAP) of TGFβ1
and 3, and LAPβ1a n dβ3 were demonstrated to be bona
ﬁde ligands for αvβ6[ 47, 48]. Cells expressing the αvβ6
integrin were shown to generate TGFβ activity that could
be detected by an in vitro TGFβ reporter assay, and this
activity was dependent upon cell-cell contact and could be
speciﬁcally blocked with antibodies to αvβ6[ 45]. Microarray
analysis of lungs from mice treated with bleomycin revealed
al a r g eg r o u po fT G F β-inducible genes that were induced
at much lower levels in the β6 knockout mice compared
with wild-type mice [49]. Collectively, these data provide
strong evidence that the αvβ6 integrin on lung epithelial
cellsisanimportant regulatorofTGFβ activation.Activation
could be inhibited by blocking actin polymerization [45]
and by inhibitors of Rho kinase [50], suggesting a role for
force generation by the actin cytoskeleton which presumably
alters the conformation of latent complexes tethered to the
extracellular matrix by matrix-bound LTBP, allowing for
exposureoftheactiveTGFβ cytokineanditsinteractionwith
TGFβ receptors.
RegulationofTGFβ activityinthelungwasfoundtoplay
an important role in the maintenance of alveolar homeosta-
sis. Low-grade inﬂammation in the lungs of the β6 knockout
mice was characterized by increased numbers of alveolar
macrophages, neutrophils, lymphocytes, and eosinophils,
and this inﬂammation was reversed by transgenic over-
expression of constitutively active TGFβ [44]. Microarray
analysis of β6 deﬁcient lungs showed more than a 20-
fold increase in the expression of matrix metalloproteinase
12 (MMP12) [49]. This protease, which is predominantly
expressed by macrophages, preferentially degrades elastin,
and has been implicated in the pathogenesis of emphysema.
Emphysema was noted in older β6 deﬁcient mice, and
crossing the β6 deﬁcient mice with mice lacking MMP12
completelyrescuedthisphenotype.Expressionofawild-type
form of the β6 integrin prevented emphysema development,
while expression of a mutant β6 integrin subunit unable
to support TGFβ activation did not prevent emphysema
development. Studies have shown that the development
of emphysema in β6 deﬁcient mice correlates tightly with
the upregulation of MMP12, suggesting that MMP12 could
serve as a surrogate biomarker to assess for this particular
consequence [44].4 International Journal of Rheumatology
5. Rationale for αvβ6 InhibitioninSScILD
SSc ILD can be histopathologically classiﬁed as nonspe-
ciﬁc interstitial pneumonia (NSIP) or usual interstitial
pneumonia (UIP) [51–54]. NSIP is the more commonly
encountered histopathologic subtype, comprised of varying
degrees of inﬂammation and ﬁbrosis, with some forms being
predominantly inﬂammatory (cellular NSIP) and others
primarilyﬁbrotic(ﬁbroticNSIP).Itremainsunclearwhether
cellular NSIP and ﬁbrotic NSIP represent a progression of
one underlying disease process or rather two separate disease
phenotypes, which in some cases can coexist within the
same patient [55]. UIP is the pathologic pattern observed
in idiopathic pulmonary ﬁbrosis (IPF) and can also be
seen in SSc ILD. UIP consists of interstitial ﬁbrosis in a
patchy pattern, honeycomb changes (both macroscopic and
microscopic), and foci of ﬁbroblastic proliferation. Although
the UIP pattern in SSc is less commonly encountered
clinically, it can be seen with increased frequency in patients
with more severe ﬁbrotic lung disease, including those with
end-stage SSc ILD requiring lung transplant.
Currently, there are no highly eﬀective agents for the
treatment of ﬁbrotic lung diseases. Several studies using
anti-TGFβ agents have demonstrated protection from lung
ﬁbrosis in disease models [46, 56, 57]. Given the homeostatic
roles of TGFβ in inﬂammation, immune regulation, and
carcinogenesis, perhaps a better strategy for TGFβ inhibition
would be to speciﬁcally target tissue-restricted activators of
TGFβ such as the αvβ6 integrin. In patients with IPF and
SSc ILD with a UIP pattern, the αvβ6 integrin is highly
upregulated on lung epithelium, implicating this pathway in
TGFβ activation [56]. In the only published report to date,
upregulation of αvβ6 was found on lung epithelium in seven
out of seven SSc patients with UIP and in a single patient
with SSc ILD who had ﬁbrotic NSIP, but not in patients with
cellular NSIP, however, the numbers of patients with NSIP
analyzed were too small to draw meaningful conclusions
[56]. It would therefore be important to better characterize
whether upregulation of αvβ6 speciﬁcally segregates with the
UIP and ﬁbrotic NSIP subsets of SSc ILD, and what role, if
any, this integrin plays in the cellular NSIP subset. Anecdotal
evidence and case series suggest that immunomodulators
might more eﬀectively target the cellular NSIP subset of SSc
ILD, whereas the ﬁbrotic NSIP and UIP subsets are thought
to be more recalcitrant to currently available therapies [58].
Of particular interest, a mouse model of radiation-induced
lung ﬁbrosis identiﬁed a sharp upregulation of αvβ6e x p r e s -
sion by immunohistochemical analysis at 18 weeks following
radiation challenge, with staining seen only in regions of
ﬁbrosis [46] and similar upregulation in ﬁbrotic regions was
found in lungs of IPF patients [56]. It thus appears that
the induction of αvβ6 correlates closely with ﬁbrosis and
that this integrin is often present at high concentrations in
regions where active TGFβ could be contributing to disease
progression.
A highly potent-blocking antibody to the αvβ6 integrin
was developed and shown to prevent ﬁbrosis in mouse
models of bleomycin- and radiation-induced lung ﬁbrosis
[46, 56]. In these studies, near maximal eﬀects on collagen
production were obtained at 1mg/kg weekly dosing of
the antibody. Importantly, a treatment (as opposed to
prophylaxis) trial was performed in mice by giving the
αvβ6-blocking antibody at day 15 following intratracheal
bleomycin administration, and decreased ﬁbrosis at day 60
wasobservedusingthehydroxyprolineassaytomeasurelung
collagen content. Given the ﬁnding of low-grade inﬂamma-
tion in the lungs of the β6 deﬁcient mice [43]a sw e l la st h e i r
late stage development of emphysema, a process that was
dependent on MMP12 [44], a concerted eﬀort was made to
characterize whether a similar inﬂammatory phenotype with
elevated MMP12 levels was observed in mice receiving the
αvβ6-blocking antibody. Transcript proﬁling of the lungs of
micetreatedwithhighdoses(10mg/kg)oftheαvβ6blocking
antibody paralleled the changes seen in β6 integrin knockout
mice, including upregulation of MMP12 levels. Importantly,
at lower doses of the αvβ6 blocking antibody (1mg/kg or
3mg/kg), MMP12 induction was greatly diminished [56],
and BAL cell counts and inﬂammatory cytokines were not
diﬀerent than in saline-treated mice [46, 56]. At these lower
doses of blocking antibody, signiﬁcant inhibition of collagen
production was still observed, as assessed by an in vivo
collagenluciferasereportersystem,suggestingthattheantiﬁ-
brotic eﬀect of αvβ6 inhibition could be uncoupled from
the proinﬂammatory eﬀect. Induction of TGFβ activation
by bleomycin, as measured by phospho-Smad levels in lung
lysates, was completely blocked at the 3mg/kg but not by
the 1mg/kg dose of αvβ6 blocking antibody suggesting that
complete blockade of TGFβ signaling is not required to
achieve antiﬁbrotic eﬃcacy and inhibition of TGFβ-induced
ﬁbrosis can be achieved without excessively perturbing the
homeostatic functions of TGFβ.
Treatment of healthy, unchallenged mice with high doses
of the αvβ6 blocking antibody has been shown to lead to
mixed cellular inﬁltrates (macrophages, lymphocytes, neu-
trophils) in lung tissue, not dissimilar to the inﬂammation
seeninthe β6knockout mice.However,long-term treatment
of healthy primates with a humanized form of the same
αvβ6 blocking antibody leads to a minimal to mild increase
in lung macrophages, which resolves completely following
discontinuation of treatment, with no increase in mixed
cellular inﬂammation (unpublished observations). These
ﬁndings have suggested that inhibition of αvβ6d o e sn o t
induce the same degree of inﬂammation in primates as seen
in mice. Additionally, no evidence of emphysema has been
observed after 6 months of weekly dosing with high doses of
αvβ6 antibody in mice or primates and there has been no
evidence of elevated MMP-12 expression in primates with
αvβ6 antibody treatment as observed in mice.
6. Conclusions
Inhibition of αvβ6 as a means of locally dampening TGFβ
activation by epithelial cells provides a rational therapeutic
approach for conditions such as lung ﬁbrosis. Importantly,
the antiﬁbrotic eﬀect of αvβ6 inhibition can be achieved at
a dose that is uncoupled from its proinﬂammatory eﬀect
in mice [46, 56]. A phase II trial using a humanized αvβ6
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be underway, and these results should be of considerable
interest to the SSc community. Evaluation of the utility of
inhibition of αvβ6-mediated TGFβ activation in SSc ILD,
particularly the UIP and ﬁbrotic NSIP subgroups, may
be worth considering, especially if these early studies in
IPF prove promising. In addition, recent data implicate
an important role for epidermal keratinocytes in SSc skin
ﬁbrosis [59]. αvβ6 is induced on injured keratinocytes in
other settings, so the expression of αvβ6 should be more
closely evaluated in skin samples from SSc patients to
determine whether a subset of these patients might also
beneﬁt from αvβ6 blockade for treatment of skin ﬁbrosis.
GiventheknownheterogeneityofSScwithinandbeyond
the limited and diﬀuse subsets [60, 61], the inhibition of
epithelial αvβ6-mediated TGFβ activation may not address
some of the other manifestations of SSc, in particular the
vascular complications in which endothelial injury has been
posited as an initiating mechanism. In fact, it is unlikely
that any single treatment strategy will eﬀectively combat
the various pathologic manifestations of SSc. Whether the
mechanisms leading to ﬁbrosis of the skin and other internal
organs in SSc are dependent upon αvβ6-mediated TGFβ
activationremainstobedetermined.Additionalmechanisms
involved in TGFβ activation, such as the integrins αvβ3,
αvβ5, and αvβ8, could be playing a contributory role, but
discussion of this is beyond the scope of the current paper.
Importantly, when considering strategies that target
TGFβ activity, potential side eﬀects should be carefully mon-
itored, such as the development of aberrant inﬂammation
or cancer. However, in light of the morbidity and mortality
associated with ﬁbrotic lung diseases, especially IPF or the
more ﬁbrotic phenotypes of SSc ILD (UIP and ﬁbrotic
NSIP), perhaps these treatment risks can be justiﬁed given
the lack of alternatives short of lung transplantation in
some cases. TGFβ activity seems to be the “Achilles heel”
of pulmonary ﬁbrosis, and the ability to locally inhibit its
activity presents an attractive strategy that may likely be met
with clinical success.
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